Living ESTRO/OligoCare review maps safety signals for SRT with modern systemic therapy
Across 7,694 patients, most SRT–systemic therapy combinations appeared tolerable, but BRAF/MEK inhibitors, T-DM1 and liver SRT showed caution signals.
Latest research
Search the archiveMost pT4 laryngeal cancer patients started postoperative RT beyond six weeks
Only 21% started PORT within 42 days after laryngectomy, while each additional week of delay was associated with 3.7% higher mortality.
Baseline urinary symptoms predicted late GU toxicity after hypofractionated prostate RT
Each one-point increase in baseline IPSS independently increased the odds of late grade ≥2 GU toxicity by 11%.
Elevating skin markers simplified proton CT simulation without sacrificing geometric accuracy
A 1.5–3.0 mm foam elevation reduced marker contouring time by 30–37% while keeping average positional error near 1 mm.
Carbon-ion radiotherapy showed feasibility for unresectable radiation-induced sarcoma
In eight previously irradiated patients, CIRT achieved 71% one-year local control and 75% survival, with grade ≥3 toxicity in 25%.
Personalized RT strategies are moving locally advanced NSCLC beyond the PACIFIC template
Modern LA-NSCLC RT is shifting toward selective escalation, de-escalation and organ sparing, increasingly guided by patient risk and tumor biology.
Monte Carlo grid size materially changed apparent plan quality in liver SBRT
A 3-mm grid cut Monaco calculation time about threefold but altered target, conformity and dose-falloff metrics despite similar gamma QA.
SABR controls oligometastatic breast lesions well, but systemic benefit remains uncertain
SABR achieved 92.5% one-year local control in oligometastatic breast cancer, while pooled randomized evidence did not definitively establish a PFS benefit.
36.25 Gy/5 showed similar five-year control to 40 Gy/5 in prostate SBRT
After propensity matching, five-year PSA recurrence-free survival was 94.5% with 36.25 Gy versus 93.2% with 40 Gy.
National audit-driven changes halved severe late GI toxicity after prostate radiotherapy
After a national audit triggered pathway redesign, severe late GI toxicity after prostate EBRT fell from 16% to 7.5%.
Omitting CTV reduced toxicity without compromising outcomes in limited-stage SCLC
After matching 530 patients, CTV omission preserved survival and recurrence patterns while substantially reducing pneumonitis and esophagitis.
Adaptive IMPT preserved gross tumor dose despite frequent ITV undercoverage in esophageal cancer
ITV underdosage occurred in 21% of distal esophageal IMPT patients, yet no GTV underdosage occurred and tumor response was unchanged.
Synthetic CT from UTE-MRI reproduced lung radiotherapy dose with high accuracy
UTE-MRI-derived synthetic CT produced <1% target-dose differences and a 95.4% gamma pass rate at 2%/2 mm.
Deep learning halved ventricular and brainstem contouring time in pediatric radiotherapy
MRI-based nnU-Net segmentation achieved Dice scores ≥0.90 and reduced clinical contouring workflow time by more than 50%.
ctDNA clearance after palliative RT tracked longer survival in advanced melanoma
One-year survival was 83% after ctDNA clearance versus 21% when ctDNA increased after RT during immune checkpoint inhibition.